Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Net Income (2016 - 2025)

Historic Net Income for Harvard Bioscience (HBIO) over the last 16 years, with Q3 2025 value amounting to -$1.2 million.

  • Harvard Bioscience's Net Income rose 7430.24% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.8 million, marking a year-over-year decrease of 27876.57%. This contributed to the annual value of -$12.4 million for FY2024, which is 26325.04% down from last year.
  • Harvard Bioscience's Net Income amounted to -$1.2 million in Q3 2025, which was up 7430.24% from -$2.3 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Net Income registered a high of $2.4 million during Q2 2022, and its lowest value of -$50.3 million during Q1 2025.
  • Its 5-year average for Net Income is -$4.2 million, with a median of -$1.3 million in 2023.
  • The largest annual percentage gain for Harvard Bioscience's Net Income in the last 5 years was 69048.78% (2022), contrasted with its biggest fall of 189411.76% (2022).
  • Harvard Bioscience's Net Income (Quarter) stood at $590000.0 in 2021, then plummeted by 466.78% to -$2.2 million in 2022, then increased by 15.99% to -$1.8 million in 2023, then skyrocketed by 102.75% to $50000.0 in 2024, then plummeted by 2568.0% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, -$2.3 million for Q2 2025, and -$50.3 million during Q1 2025.